Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medicure Inc V.MPH

Alternate Symbol(s):  MCUJF

Medicure Inc. is a pharmaceutical company. It is focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market. The focus of it is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through the Company's United States subsidiary, Medicure Pharma Inc. It also operates Marley Drug Inc. (Marley Drug), a pharmacy subsidiary servicing all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving access to medication for all Americans together with exceptional customer service and free home delivery. AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome. It also develops pyridoxal 5'-phosphate analogues (P5P Analogues), the processes for their preparation, compositions containing P5P Analogues.


TSXV:MPH - Post by User

Bullboard Posts
Comment by eSnowdenon Nov 22, 2017 8:25am
165 Views
Post# 27009723

RE:Congrats MPH - Great 3rd Quarter - expect $10 to $15 soon

RE:Congrats MPH - Great 3rd Quarter - expect $10 to $15 soon
The $105 million dollar purchase price for Apicore is in US Dollars--around $135 million Canadian. The debt, $61 million in total, is 100% Canadian. The purchase was most likely a US co., so there are some extremely favourable exchange rate consequences. On the flip side, Aggrastat is a dead duck...generic Intergrillin, not Aggrastat patent expiration, is going to kill off Agg. The Prexxarten purchase looks good on paper, in acutualiity, it's a liquid generic formulation of an existing generic in pill form...very limited potential. A positive from that acq. is that MPH paid $600k for it, which in the pharma world, is absolutely nothing.
Bullboard Posts